Replies to post #44382 on CV Sciences Inc (CVSI)

[LEGEND1266]

That's absurd. With all of the Holiday discounts and promotions plus lots of new customers and ever growing awareness by the public. I myself have turned on a number of friends and family who are buying this product. Last December myself, friends and family spent zero on CVSI products. This December well over $1000.00. They will not only exceed projections but in fact will blow them away. And that will continue quarter after quarter. We have the number one selling CBD oil product and news and recognition is exploding as we speak. Everyone is talking about CBD oil now. Awareness along with really good results is everything. Personally the results from taking the Gold have exceeded my wildest expectations. It is the silver bullet that everyone has been looking for for improved health and attitude.

[FastMny]

Come on. How about we bet a bottle of your favorite bottle that quarterly revenues are higher than 12.5 million?

[jefra1965]

Given the industry’s robust growth momentum, we believe we have the right strategies in place and remain committed to achieve a strong 2018 finish

CV Sciences, Inc. Reports Third Quarter 2018 Financial Results
“We are encouraged by our performance as we delivered another strong quarter, including our third consecutive quarter of profitability. This was led by initiatives that include accelerating our brand recognition and brand loyalty and growing sales distribution channels that have generated triple-digit year-over-year revenue growth and double-digit sales growth on a sequential quarterly comparison. The demand continues to respond strongly to our leading PlusCBDTM product line, #1 in the hemp CBD product category in the natural products retail channel and we believe this is just the beginning for the vast and nascent hemp CBD market. Most notably during the quarter, we earned the industry’s first self-affirmed Generally Recognized as Safe (GRAS) status for our Gold Formula product line, a move that shows our dedication to building consumer confidence, trust and safety of our products. In conjunction with that, our product innovation was on full display with the introduction of our new PlusCBD OilTM Gummies in two flavors, Cherry Mango and Citrus Punch as additional factors for driving revenue,” stated Joseph Dowling, Chief Executive Officer of CV Sciences.
Mr. Dowling added, “Our drug development program is making steady progress in advancing our proprietary lead drug candidate - CVSI-007 - which addresses the multibillion dollar smokeless tobacco use and addiction market. We continue to make progress with our pre-clinical program, anticipating filing an Investigational New Drug application in 2019. We are confident that our continued growth and profitability will allow us to initially pursue our drug development plans without the need for additional outside capital in the near term. Given the industry’s robust growth momentum, we believe we have the right strategies in place and remain committed to achieve a strong 2018 finish.”

[Deetew]

He did say he would sacrifice short-term gains for long-term gains, but plus cbd oil has been flying off the shelves. I think it’s quite possible that profits could be great while NI could suffer a bit from reinvestment into the business. It’s a total mystery though; we’ll have to see.